Review Degrons in cancer

Understanding protein degradation signals and systems reveals targets for cancer therapy.
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Source Type: news

Related Links:

In conclusion, our findings indicate that GPR120 acts as a cancer-promoting receptor in the development of breast cancer. Therefore, GPR120 is expected to be a potential new target for cancer therapy.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
Abstract PURPOSE: To understand the meaning and impact for adult patients with cancer (past or present) of creating a digital story related to their cancer experience. PARTICIPANTS & SETTING: 10 participants made digital stories with the help of a research assistant trained in digital storytelling. This research took place in a large, urban center in Calgary, Alberta, Canada. METHODOLOGIC APPROACH: This research was done in the tradition of philosophical hermeneutics. Ten one-on-one interviews were conducted, and data were analyzed using an interpretive qualitative methodology. FINDINGS: Finding...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
n K. Iyer Targeting immune checkpoint molecules such as programmed death ligand-1 (PDL1) is an emerging strategy for anti-cancer therapy. However, transient expression of PDL1 and difficulty in tumor stroma penetration has limited the utility of anti-PDL1 therapy. To overcome these limitations, we report a new conjugate between the clinically approved PDL1 antibody (PDL1 AB) and drug Doxorubicin (Dox), named PDL1-Dox. We conjugated PDL1-Dox through a hydrazone linker containing a polyethylene glycol (PEG) spacer, which allows it to dissociate in a tumor environment and improves solubility. The purpose of using Dox is t...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The U.S. Centers for Medicare&Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including an approved registry of patient results or clinical study to monitor patients for at least two years after treatment.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The U.S. Centers for Medicare&Medicaid Services (CMS) on Friday proposed Medicare coverage of approved CAR-T cell therapies that use the patient's immune system to fight cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ConclusionOur study proves that, 11α-O-tigloyl-12β-O-acetyl-tenacigenin B, 11α-O-2-methylbutanoyl-12β-O-tigloyl-tenacigenin B and 11α-O-2-methylbutanoyl-12β-O-acetyl-tenacigenin B, which are the main constituents of ETA, are active inhibitors of CYP3A4 with potential to increase therapeutic efficacy of anticancer drugs that are substrates of CYP3A4. Tenacigenin B derivatives with C-11 and C-12 ester group substitutions, or at least a large part of them, are active components in ETA and M. tenacissima to enhance in vivo antitumor efficacies of paclitaxel.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 13 February 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Sharad S. Singhal, Ravi Salgia, Sulabh Singhal, David Horne, Sanjay AwasthiAbstractBreast cancer (BC) is the most common cancer among women worldwide. Due to its complexity in nature, effective BC treatment can encounter many challenges. The human RALBP1 gene encodes a 76-kDa splice variant protein, RLIP (ral-binding protein1, RalBP1), a stress-protective mercapturic acid pathway (MAP) transporter protein, that also plays a key role in regulating clathrin-dependent endocytosis (CDE) as a Ral effector...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Featuring Our Colorectal CAFSCAFs play a central role in the Tumor Microenvironment (TME). The TME has been identified as one of the driving factors of tumor progression and invasion. Inside this microenvironment, CAFs, a type of perpetually activated fibroblasts, have been implicated to have a strong tumor modulating effect and play a key role in areas such as drug resistance.This makes CAFs a target for cancer therapies. The challenge is the TME is heterogeneous making it a challenge to derive homogeneously relevant populations for basic research and drug discovery. This new study uses ourColorectal CAFs to identify...
Source: Neuromics - Category: Neuroscience Tags: CAFs Cancer Associated Fibroblasts CD90 colorectal CAFs Colorectal Cancer Flow cytometry PDGF Source Type: news
It seems reasonable to think that sabotaging the lengthening of telomeres might prove to be the basis for a universal cancer therapy, capable of shutting down all cancers. Unfettered telomere lengthening is required by all cancers in order to permit rampant replication and growth. Without that capability, the cancer will wither. Telomere length is a part of the mechanism limiting cell replication; cells lose a little of that length with each cell division, and short telomeres force senescence or self-destruction via programmed cell death. In normal tissues only stem cells use telomerase in order to maintain lengthy telomer...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Environmental Health